Literature DB >> 27430434

microRNA-7 regulates cell growth, migration and invasion via direct targeting of PAK1 in thyroid cancer.

Kai Yue1, Xudong Wang1, Yansheng Wu1, Xuan Zhou1, Qinghua He1, Yuansheng Duan1.   

Abstract

The expression and function of microRNA-7 (miR-7) has been studied in a variety of different cancer types. However, to date, no studies have investigated the expression of miR‑7 in human thyroid cancer. In the present study, the expression levels and biological function of miR‑7 were investigated in human thyroid cancer, with the aim of evaluating whether it may serve as a therapeutic biomarker. The expression levels of miR‑7 in human thyroid cancer tissues, matched, adjacent normal tissues, normal thyroid tissues and human thyroid cancer cell lines were determined using RT‑qPCR and western blot analysis. To explore the functional role of miR‑7 in human thyroid cancer cell lines, MTT assays, cell migration and invasion assays were employed. TargetScan software identified p21 activated kinase‑1 (PAK1) as a putative interacting partner of miR‑7. Therefore, functional assays were performed to explore the effects of endogenous PAK1 in thyroid cancer. In the present study, miR‑7 was significantly downregulated in thyroid cancer tissues and cells compared with normal thyroid tissue samples. A correlation between miR‑7 expression and thyroid tumor stage was also observed. Ectopic expression of miR‑7 was found to suppress the proliferation, migra-tion and invasion of thyroid cancer cells in vitro. Dual-luciferase reporter assays demonstrated that PAK1 was a direct target of miR-7 in vitro. RT-qPCR and western blot analysis demonstrated that miR‑7 negatively regulates PAK1 protein expression but has no effect on PAK1 mRNA expression. Knockdown of PAK1 expression markedly suppressed thyroid cancer cell proliferation, migration and invasion. These results suggest that miR‑7 functions as a tumor suppressor by targeting PAK1 directly and may therefore present a novel therapeutic target for the treatment of thyroid cancer.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27430434     DOI: 10.3892/mmr.2016.5477

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  16 in total

Review 1.  p21-Activated Kinases in Thyroid Cancer.

Authors:  Luis Bautista; Christina M Knippler; Matthew D Ringel
Journal:  Endocrinology       Date:  2020-08-01       Impact factor: 4.736

2.  Hypermethylation of microRNA-497-3p contributes to progression of thyroid cancer through activation of PAK1/β-catenin.

Authors:  Yuxia Fan; Xin Fan; Hao Yan; Zheng Liu; Xiaoming Wang; Qingling Yuan; Jie Xie; Xiubo Lu; Yang Yang
Journal:  Cell Biol Toxicol       Date:  2022-01-23       Impact factor: 6.691

3.  Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells.

Authors:  Shaoyan Feng; Yu Wang; Rongkai Zhang; Guangwei Yang; Zibin Liang; Zhiwei Wang; Gehua Zhang
Journal:  Onco Targets Ther       Date:  2017-05-02       Impact factor: 4.147

4.  Emerging roles of the long non-coding RNA 01296/microRNA-143-3p/MSI2 axis in development of thyroid cancer.

Authors:  Zheng-Lin Wang; Cong Wang; Wei Liu; Zhi-Long Ai
Journal:  Biosci Rep       Date:  2019-11-29       Impact factor: 3.976

Review 5.  Regulators of glucose uptake in thyroid cancer cell lines.

Authors:  Shabnam Heydarzadeh; Ali Asghar Moshtaghie; Maryam Daneshpoor; Mehdi Hedayati
Journal:  Cell Commun Signal       Date:  2020-06-03       Impact factor: 5.712

Review 6.  Circular RNAs as novel potential biomarkers for pancreatic cancer.

Authors:  Shanshan Liu; Qiuyue Li; Yan Ma; Christopher Corpe; Jin Wang
Journal:  J Cancer       Date:  2021-06-01       Impact factor: 4.207

7.  Integrated Characterization of MicroRNA and mRNA Transcriptome in Papillary Thyroid Carcinoma.

Authors:  Azliana Mohamad Yusof; Rahman Jamal; Rohaizak Muhammad; Shahrun Niza Abdullah Suhaimi; Isa Mohamed Rose; Sazuita Saidin; Nurul-Syakima Ab Mutalib
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-16       Impact factor: 5.555

8.  MiR-26a/miR-26b represses tongue squamous cell carcinoma progression by targeting PAK1.

Authors:  Zhenxing Wei; Kunpeng Chang; Chongsheng Fan; Yang Zhang
Journal:  Cancer Cell Int       Date:  2020-03-14       Impact factor: 5.722

Review 9.  Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.

Authors:  Myriem Boufraqech; Naris Nilubol
Journal:  Cancers (Basel)       Date:  2019-12-10       Impact factor: 6.639

10.  miR‑7/SP1/TP53BP1 axis may play a pivotal role in NSCLC radiosensitivity.

Authors:  Genyan Guo; Lingling Li; Guanchu Song; Jie Wang; Ying Yan; Yuxia Zhao
Journal:  Oncol Rep       Date:  2020-10-23       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.